Bavelloni, A., Piazzi, M., Ramazzotti, G., Fiume, R., Blalock, W. and Faenza, I. (2017) “PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma”, Italian Journal of Anatomy and Embryology, 122(1), p. 21. Available at: https://oajournals.fupress.net/index.php/ijae/article/view/1730 (Accessed: 1 May 2024).